An open-label Phase 3 study of S-474474 in patients with essential hypertension - Evaluation of the safety and efficacy of long term use -
Latest Information Update: 03 Jun 2016
Price :
$35 *
At a glance
- Drugs Irbesartan/trichlormethiazide (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Shionogi
- 03 Jun 2016 New trial record